-
    About Worldwide  |     FAQs    |    Careers    |        Media Center  |    Taj Pharmaceuticals |  World   |    TAJ Group
    © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

pharmaceutical industry has emerged as a major sector of the world

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredients  TAJ PHARMACEUTICALS LIMITED
   
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
   
difference in the south East Asian
 

 

 

 

 

 

 

 

 

 

HOME >> Asia

ASIAN PHARMA INDUSTRY



market map in WorldThe pharmaceutical industry has emerged as a major sector of the world economy only during the second half of the 20th Century. Today, it is a 350 billion dollar industry spread across mainly in three continents namely North America, Europe and parts of Asia. Almost 47 percent of the world pharmaceutical market is controlled by North America, followed by Europe with a market share of 24 percent. Japan alone has a market share of 16 percent in Asia. Rest of the pharmaceutical market is in South East Asia, Latin America, Africa and Australia. Growth of pharmaceutical industry has taken place in South East Asia only during the last 15 years. India, China and South Korea have now been recognised as the leading players in South East Asian region producing and exporting a large number of bulk drugs and some quantum of dosage forms to the developed world. India emerged as key supplier of several bulk drugs to the US and European markets during the second half of eighties. China entered the world pharmaceutical markets as a major supplier of bulk drugs in the nineties with much lower prices and in direct competition with India. Today, it is one of the major suppliers of bulk drugs to the formulation producers worldwide. Chinese bulk drugs are also being accepted as quality APIs. Countries like Singapore, Malaysia, Indonesia, Thailand, Taiwan and Hong Kong are making serious efforts to build up strong domestic pharmaceutical bases of late although currently MNCs dominate these markets.

An important difference in the south East Asian countries unlike in India is the relatively higher standards of manufacturing practices followed by the pharma companies. India, on other hand, has much larger number of pharmaceutical companies but a majority of them with poor manufacturing standards. Hardly 200 out of a total of 20,000 units have any acceptable manufacturing standards in India. With mandatory implementation of GMP by December, 2003 the face of Indian pharmaceutical industry will also be changing with vast number of small operators will be closing shops for good. An important incentive for the pharma companies in South East Asian countries is the exploding demand for generics in the US and European markets in the coming years. With increasing emphasis on cut in healthcare costs in these developed markets, governments are keen to use more of generics instead of branded products. It is estimated that almost 40 percent of annual consumption of medicines in the US and Europe is going to be generics from now onwards. Japan, the third biggest pharmaceutical market, is also looking at generics as an ideal option. For a growing pharmaceutical industry in South East Asia, the spurt in demand for generics should prove to be a right opportunity to cash on. The decision of leading pharmaceutical manufacturing countries of Asia to form a federation of Asian pharmaceutical trading association last December will be the first serious step to build Asia as a powerful manufacturing base on par with North America and Europe.

New Added Products:
Phenobarbital sodium [57-30-7],Acenocoumarol [152-72-7],Esomeprazole Magnesium,Famotidine,Ibuprofen,Lacidipine,Levetiracetam,Losartan Potassium,
Montelukast Sodium,Naproxen,Norfloxacin,Olmesartan,Omeprazole Sodium,
Pantoprazole,Quetiapine Fumarate,TrandolaprilZolmitriptan

New Product : Caffeine new Oseltamivir Phosphate[58-08-2]
Taj pharmaceuticals API Logo

taj group

 

Asia

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
Active Pharmaceutical Ingredients manufacturer, exporter, drug ingredients, pharmaceuticals, India
© 2004 - 2009
Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.